DEV: Developing alternative routes of immunotherapies with innovative drugs for neurodegenerative and gastrointestinal diseases. Our major focuses are nasal immunotherapy for Secondary Progressive Multiple Sclerosis, oral immunotherapy for Crohn's Disease and inhalation therapy for lung diseases.

Learn more about Tiziana   Tiziana Investor Deck   Scientific Presentations and Updates

FDA Grants Permission to Enroll up to 8 Additional Secondary Progressive Multiple Sclerosis (SPMS) Patients in the Expanded Access Program with Intranasal Foralumab

05 April 2022

  • This Intermediate-Size Patient Population Expanded Access program will follow the same clinical dosing regimen as the two ongoing single-patient expanded access programs in SPMS patients.
  • Tiziana recently reported clinical data from the first SPMS patient showing beneficial responses following six months...
Read more

Tiziana Announces Initiation of Phase 1b Clinical Trial in Crohn’s Disease Patients to Evaluate Oral Capsules of Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody

25 March 2022

  • This clinical trial, the first-ever oral immunotherapy for patients with mild-to-moderately active Crohn's Disease, is anticipated to be completed by Q4, 2022.

New York, March 25, 2022 – Tiziana Life Sciences (Nasdaq: TLSA) ("Tiziana" or the "Company"), a biotechnology company...

Read more

Article: Single-patient data suggest Tiziana nose a better way with CD3 in MS

16 March 2022

Bioworld have published an article on Tiziana Life Sciences SPMS 6-month data using intranasal foralumab.

Read more

Our Mission

Our mission is to bring breakthrough therapies to patients with the aim of treating SPMS, Crohn's Disease, lung diseases and optimizing health outcomes.

Learn more

Clinical Candidates

Our major clinical assets are supported by extensive worldwide issued patents and pending patent applications covering composition of matter, formulation technologies, manufacturing processes and disease indications.

Pipeline

Foralumab

Foralumab is a fully human anti-CD3 monoclonal antibody (mAb) for treatment of Crohn’ s Disease and neurodegenerative indications.

Learn more about Foralumab

Anti IL-6 Receptor mAb
(IL-6R:TZLS-501)

We are developing a fully human monoclonal antibody (mAb) targeting the receptor for IL-6 as a potential treatment for lung diseases.

Learn more about Anti IL-6R

Milciclib

Milciclib is the Company’s Phase 2 clinical candidate for the treatment in cancer indications. The company is exploring the combination of milciclib and gemcitibine in NSCLC patients with pan KRAS+ mutations.

Learn more about Milciclib

Clinical Trials

Tiziana is currently conducting clinical development programs for Foralumab, Anti IL-6R and Milciclib

Foralumab

Tiziana reported postive clinical data in a Phase I clinical trial of nasally-dosed Foralumab in healthy subjects in collaboration with Dr. Howard Weiner at Brigham and Women’s Hospital in Boston. Phase 2 for both orally administered Foralumab for the treatment of Crohn's disease and nasally administered Foralumab for the treatment of Pro-MS is anticipated to be complete in Q2 2021.

See more Foralumab clinical trials

Anti IL-6R mAb (TZLS-501)

Manufacturing of clinical supplies for a Phase 1 study is anticipated to be completed in 3Q/4Q 2022 and we plan to initiate a Phase 2 trial in Q4 2022/1Q 2023.

Milciclib

We are exploring a study to evaluate the combination of milciclib and gemcitabine in NSCLC subjects with associated pan KRAS-positive mutations.

See more Milciclib clinical trials

Tiziana Life Sciences is listed on NASDAQ